Search Result

Results for "

PD-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (162) Adenosine Receptor (1) Akt (1) Apoptosis (9) Aryl Hydrocarbon Receptor (3) Bcr-Abl (2) c-Fms (2) c-Kit (2) c-Met/HGFR (1) c-Myc (1) CD38 (1) COMT (2) CTLA-4 (4) DGK (8) Discoidin Domain Receptor (2) Dopamine Receptor (2) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Endogenous Metabolite (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FLT3 (2) GCGR (1) Glucosidase (2) HBV (3) HDAC (2) Histone Demethylase (1) iGluR (3) IKK (1) Immune Checkpoint (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) JNK (1) Keap1-Nrf2 (2) LAG-3 (2) Ligands for Target Protein for PROTAC (2) LRRK2 (2) MAP4K (2) mGluR (3) Monoamine Oxidase (7) NAMPT (1) NF-κB (2) P-glycoprotein (1) PARP (2) Phosphatase (2) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) PROTAC Linkers (3) PROTACs (1) Reactive Oxygen Species (1) ROR (1) STING (2) Target Protein Ligand-Linker Conjugates (2) TNF Receptor (2) Toll-like Receptor (TLR) (4) Trk Receptor (2) VEGFR (3) α-synuclein (10)
By Research Areas:	Cancer (197) Infection (8) Inflammation/Immunology (55) Metabolic Disease (2) Neurological Disease (39)
Click Chemistry:	Azide (1)

248

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator ^[1].

PD-1-IN-24	PD-1/PD-L1	Cancer
PD-1-IN-24 (compound 1) is an orally active *PD-1* inhibitor ^[1].

PD-1-IN-17	PD-1/PD-L1	Cancer
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM ^[1].

PD1-PDL1-IN 1	PD-1/PD-L1	Inflammation/Immunology
PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator ^[1].

PD-1-IN-18	PD-1/PD-L1	Inflammation/Immunology
PD-1-IN-18 is a *PD1* signaling pathway inhibitor, which acts as an immunomodulator.

PD1-PDL1-IN 2	PD-1/PD-L1	Cancer
PD1-PDL1-IN 2 (ZE132) is a potent and selective *PD-1/PD-L1* inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β ^[1].

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM ^[1].

PD-1-IN-20	PD-1/PD-L1	Cancer
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 ^[1].

PD-1-IN-17 TFA	PD-1/PD-L1	Cancer
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM ^[1].

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

PD-1/PD-L1 antagonist 1	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM ^[1].

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

PD-1/PD-L1-IN-15	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch ^[1].

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between **PD-1 and PD-L1, with an IC₅₀** of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% ^[1].

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1. PD-1*/PD-L1-IN-43 can be used in anti-tumor studies ^[1].

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases ^[1].

MAX-10181 PD-1/PD-L1-IN-30	PD-1/PD-L1	Cancer
MAX-10181 (PD-1/PD-L1-IN-30) is a *PD-1/PD-L1* binding inhibitor, with an IC₅₀ value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases ^[1].

PD-1/PD-L1-IN 5 TFA	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1*/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice ^[1].

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment ^[1].

Evixapodlin GS-4224; PD-1/PD-L1-IN 7	PD-1/PD-L1 HBV	Infection Cancer
Evixapodlin (GS-4224) is a *human PD-1/PD-L1 protein/protein interaction* inhibitor with an IC₅₀ of 0.213 nM. Evixapodlin has anticancer and antiviral functions ^[1].

PD-1-IN-25	PD-1/PD-L1	Cancer
PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ T cell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth ^[1].

PD-1-IN-22	PD-1/PD-L1	Cancer
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM ^[1].

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model ^[1].

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

PD-1/PD-L1-IN 5	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity ^[1].

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer ^[1].

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy ^[1].

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

PD-1/PD-L1-IN-51	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity ^[1].

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion ^[1].

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent *PD-1/PD-L1* inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs ^[1].

PD-1/PD-L1-IN-48	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research ^[1].

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

494 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 494 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L188

Anti-Brain Cancer Compound Library

1,460 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,460 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L184

Anti-Gastric Cancer Compound Library

649 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 649 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L079

Anti-Blood Cancer Compound Library

2,724 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2,724 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

5,275 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5,275 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

589 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 589 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind *PD-L1* protein, significantly block the interaction between *PD-1* and *PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP*-1 can be used in cancer immunotherapy research ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀?of 7.68?nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P3140A

α-Synuclein (61-75) (TFA)	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting *GLP-1R* agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an α-synuclein knockdown peptide. Tat-βsyn-degron binds toα-synuclein and reduces α-synuclein levels in primary rat cortical neuron cultures. Tat-βsyn-degron also reduces α-synuclein levels and decreases the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P99144A

*Anti-Mouse PD-1* Antibody (S-5001)**	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse *PD-1* IgG1 antibody inhibitor.

HY-P99144

*Anti-Mouse PD-1* Antibody (RMP1-14)** 4 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG2a antibody inhibitor.

HY-P9902A

*Pembrolizumab (anti-PD-1)* 2 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* ^[1] .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity ^[1].

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-P990824

*Anti-Mouse PD-1* Antibody (J43)**	Inhibitory Antibodies	Others
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-P990788

*Anti-Mouse PD-1* Antibody (29F.1A12)**	Inhibitory Antibodies	Others
Anti-Mouse PD-1 Antibody (29F.1A12) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (29F.1A12): Rat IgG2a kappa, Isotype Control (HY-P990679).

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells ^[1].

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* ^[1].

HY-P99106

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to *PD-1* ^[1] .

HY-P99887

Pimivalimab JTX-4014	PD-1/PD-L1	Cancer
Pimivalimab (JTX-4014) is a *PD-1* inhibitor. Pimivalimab can be used for the research of solid tumor ^[1].

HY-P99387

TSR-033	LAG-3	Cancer
TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity ^[1].

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and *PD-1* and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity ^[1].

HY-P9902

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research ^[1] .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma ^[1].

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific *PD-1/LAG-3* dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity ^[1] .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1 antibody* (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block *PD-1* and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) ^[1] .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) ^[1].

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells ^[1].

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research ^[1] .Latikafusp may lead to the development of immunogenicity-mediated responses .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1] .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation ^[1].

HY-P990072

Lipustobart	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 *(programmed cell death 1, PD1, PD-1, CD279)* humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity ^[1].

HY-P9971

Camrelizumab 3 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer ^[1].

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo ^[1].

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Cancer
Rosnilimab is a humanized IgG1-κ antibody targeting to *PD-1* ^[1] .

HY-P99957

Zeluvalimab AMG-404	PD-1/PD-L1	Cancer
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer ^[1].

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 ^[1].

HY-P99679

Izuralimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 ^[1].

HY-P9903

Nivolumab Maximum Cited Publications 20 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma ^[1] .

HY-P9993

Peresolimab LY-3462817	PD-1/PD-L1	Cancer
Peresolimab is a humanized IgG1-κ antibody targeting to *PD-1*. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis ^[1] .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma ^[1] .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function ^[1].

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo ^[1].

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively ^[1].

HY-P99100

Visugromab 1 Publications Verification CTL-002	PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors ^[1].

HY-P99117

Cadonilimab AK104	PD-1/PD-L1 CTLA-4 Immune Checkpoint	Inflammation/Immunology Cancer
Cadonilimab (AK104) is a humanized tetravalent *IgG1* bispecific antibody targeting *PD1/CTLA4. Cadonilimab blocks both PD-1* and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) ^[1] .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1*. Garivulimab has antitumor activity ^[1].

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody ^[1]. Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P990169

*Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)*	Inhibitory Antibodies	Others
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279.

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P9919A

Durvalumab (anti-PD-L1) 5 Publications Verification MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors ^[1] .

HY-P99807

Prolgolimab BCD-100	PD-1/PD-L1	Cancer
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma ^[1].

HY-P99540

Tuvonralimab PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105	PD-1/PD-L1 CTLA-4	Cancer
Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab ^[1].

Recombinant Proteins Recommended:

PD-1

Species:	Human (15) Rhesus Macaque (4) Mouse (7) Rat (4) Cynomolgus (5) Canine (4)
Tag:	His (21) Avi (5) Fc (18)
Source:	HEK293 (36) CHO (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70676

	PD-1 Protein, Cynomolgus (147a.a, HEK293, His) Programmed cell death 1; PD-1; PD1	Cynomolgus	HEK293
	PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (147a.a, HEK293, His) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70639

	PD-1 Protein, Mouse (HEK293, Fc) Programmed cell death protein 1; PD-1; CD279; PDcd1; mPD-1	Mouse	HEK293
	The PD-1 protein is expressed on antigen-activated T cells and can induce and maintain immune tolerance to itself.PD-1 binds to CD274/PDCD1L1 and CD273/PDCD1LG2, transmits inhibitory signals, inhibits T cell activation and regulates immune responses.PD-1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70640

	PD-1 Protein, Mouse (HEK293, His) Programmed cell death protein 1; PD-1; CD279; PDcd1; mPD-1	Mouse	HEK293
	The PD-1 protein is expressed on antigen-activated T cells and can induce and maintain immune tolerance to itself.PD-1 binds to CD274/PDCD1L1 and CD273/PDCD1LG2, transmits inhibitory signals, inhibits T cell activation and regulates immune responses.PD-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73724

	PD-1 Protein, Mouse (HEK293, His-Fc) 1 Publications Verification Programmed cell death protein 1; PD1; CD279; PDCD1	Mouse	HEK293
	PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc, C-8*His labeled tag.

HY-P78191

	PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi) PDCD1; PD1; CD279; SLEB2; PD-1	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is 143 a.a., with molecular weight of 65-72 kDa.

HY-P70799

	PD-1 Protein, Human (C93S, HEK293, His) Programmed cell death protein 1; PDCD1; PD-1; hPD-1; CD279	Human	HEK293
	PD-1 protein, an inhibitory receptor on T-cells, maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It hinders T-cell activation by associating with CD3-TCR and recruiting PTPN11/SHP-2 for dephosphorylation of key signaling molecules. Tumors exploit PD-1 to weaken anti-tumor immunity, inhibiting CTLs. Blocking PD-1 pathway reverses exhausted T-cell phenotype and enhances anti-tumor response, supporting cancer immunotherapy. PD-1 Protein, Human (C93S, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag and C93S mutation. The total length of PD-1 Protein, Human (C93S, HEK293, His) is 143 a.a., with molecular weight of 23-38 kDa.

HY-P7395

	PD-1 Protein, Human (CHO, Fc) 2 Publications Verification rHuPD-1, Fc Chimera; PD1; CD279; PDCD1	Human	CHO
	PD-1 Protein, Human (CHO, Fc) suppress activating signals from the T cell receptor when bound by either of its ligands, programmed death-ligand 1 (PD-L1) or PD-L2.

HY-P70547

	PD-1 Protein, Cynomolgus (143a.a, HEK293, Fc) Programmed cell death 1; PD-1; PD1	Cynomolgus	HEK293
	PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (143a.a, HEK293, Fc) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-1 Protein, Cynomolgus (143a.a, HEK293, Fc) is 143 a.a., with molecular weight of 60-75 kDa.

HY-P700808

	PD-1 Protein, Mouse (Biotinylated, HEK293, Fc) PDCD1; PD1; CD279; SLEB2; PD-1	Mouse	HEK293
	PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1 Protein, Mouse (Biotinylated, HEK293, Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73727

	PD-1 Protein, Canine (Biotinylated, HEK293, His-Avi) Programmed cell death protein 1; PD1; CD279; PDCD1	Canine	HEK293
	Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (Biotinylated, HEK293, His-Avi) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P73341

	PD-1 Protein, Canine (HEK293, Fc) CD279; PDCD1; Programmed cell death 1; SLEB2	Canine	HEK293
	Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P7396

	PD-1 Protein, Human (143a.a, HEK293, His) 2 Publications Verification rHuPD-1, His; PD1; CD279; PDCD1	Human	HEK293
	PD-1 Protein, Human (143a.a, HEK293, His) suppress activating signals from the T cell receptor when bound by either of its ligands, programmed death-ligand 1 (PD-L1) or PD-L2.

HY-P73342

	PD-1 Protein, Canine (HEK293, His) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Canine	HEK293
	The Angiopoietin-1 Protein is a secreted glycoprotein that is a key ligand in the vascular tyrosine kinase signaling pathway. ANGPT1 stimulates angiogenesis by activating PTK2/FAK and downstream kinase MAPK1/ERK2 and MAPK3/ERK1 signaling pathways. ANGPT1 affects the proliferation, migration and differentiation of skeletal muscle cells. PD-1 Protein, Canine (HEK293, His) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-1 Protein, Canine (HEK293, His) is 145 a.a., with molecular weight of ~34.88 and 65.02 kDa.

HY-P73344

	PD-1 Protein, Human (HEK293, Fc) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, Fc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-1 Protein, Human (HEK293, Fc) is 143 a.a., with molecular weight of 55-66 kDa.

HY-P73347

	PD-1 Protein, Rat (HEK293, His) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Rat	HEK293
	Programmed cell death protein 1 (Pdcd1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. Pdcd1plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but Pdcd1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-1 Protein, Rat (HEK293, His) is 143 a.a., with molecular weight of ~30-40 kDa.

HY-P73348

	PD-1 Protein, Rat (HEK293, Fc) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Rat	HEK293
	Programmed cell death protein 1 (Pdcd1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. Pdcd1plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but Pdcd1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-1 Protein, Rat (HEK293, Fc) is 167 a.a., with molecular weight of ~118.8 & 58.4 kDa, respectively.

HY-P77509

	PD-1 Protein, Human (Biotinylated, HEK293, His) Programmed cell death protein 1; hPD-1; PDCD1; CD279	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-1 Protein, Human (Biotinylated, HEK293, His) is 143 a.a., with molecular weight of ~17.4 KDa.

HY-P73345

	PD-1 Protein, Human (HEK293, His-Fc) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, His-Fc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of PD-1 Protein, Human (HEK293, His-Fc) is 143 a.a., with molecular weight of 55-66 kDa.

HY-P73349

	PD-1 Protein, Rhesus Macaque (HEK293, Fc) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Rhesus Macaque	HEK293
	Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73350

	PD-1 Protein, Rhesus Macaque (HEK293, His) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Rhesus Macaque	HEK293
	Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-1 Protein, Rhesus Macaque (HEK293, His) is 167 a.a., with molecular weight of 33-50 kDa.

HY-P73725

	PD-1 Protein, Cynomolgus (Biotinylated, 143a.a, HEK293, Fc-Avi) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Cynomolgus	HEK293
	PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (Biotinylated, 143a.a, HEK293, Fc-Avi) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of PD-1 Protein, Cynomolgus (Biotinylated, 143a.a, HEK293, Fc-Avi) is 143 a.a., with molecular weight of ~44.5 kDa.

HY-P70525

	PD-1 Protein, Human (HEK293, mFc) Programmed cell death protein 1; hPD-1; PDCD1; CD279	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PD-1 Protein, Human (HEK293, mFc) is 147 a.a., with molecular weight of 55-70 kDa.

HY-P72406

	PD-1 Protein, Human (Biotinylated, HEK293, His-Avi) Programmed cell death protein 1; hPD-1; PDCD1; CD279	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of PD-1 Protein, Human (Biotinylated, HEK293, His-Avi) is 147 a.a., with molecular weight of 35-45 kDa.

HY-P73342A

	PD-1 Protein, Canine (HEK293, C-His) CD279; hPD-1; PDCD1; Programmed cell death 1; SLEB2	Canine	HEK293
	The Angiopoietin-1 Protein is a secreted glycoprotein that is a key ligand in the vascular tyrosine kinase signaling pathway. ANGPT1 stimulates angiogenesis by activating PTK2/FAK and downstream kinase MAPK1/ERK2 and MAPK3/ERK1 signaling pathways. ANGPT1 affects the proliferation, migration and differentiation of skeletal muscle cells. PD-1 Protein, Canine (HEK293, C-His) is the recombinant canine-derived PD-1, expressed by HEK293 , with C-6*His labeled tag. ,

HY-P70766

	PD-1 Protein, Human (147a.a, HEK293, His) Programmed cell death protein 1; hPD-1; PDCD1; CD279	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (147a.a, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-1 Protein, Human (147a.a, HEK293, His) is 147 a.a., with molecular weight of ~38.0 kDa.

HY-P73370

	PD-L2 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Rat	HEK293
	Programmed cell death 1 ligand 2 (Pdcd1lg2, Pd-l2, B7-DC) is a member of B7 family and a ligand of programmed cell death 1. Pdcd1lg2 negatively regulates activated T cell proliferation, interferon-gamma production and interleukin-10 production in a PDCD1-independent manner, or inhibits T-cell proliferation by blocking cell cycle progression and cytokine production by interacts with PDCD1, and consequently causes cancer growth and suppresses the immune system. PD-L2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73371

	PD-L2 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Rat	HEK293
	Programmed cell death 1 ligand 2 (Pdcd1lg2, Pd-l2, B7-DC) is a member of B7 family and a ligand of programmed cell death 1. Pdcd1lg2 negatively regulates activated T cell proliferation, interferon-gamma production and interleukin-10 production in a PDCD1-independent manner, or inhibits T-cell proliferation by blocking cell cycle progression and cytokine production by interacts with PDCD1, and consequently causes cancer growth and suppresses the immune system. PD-L2 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Rat (HEK293, His) is 200 a.a., with molecular weight of ~35.7 kDa.

HY-P77528

	PD-L2 Protein, Human (Biotinylated, HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73369

	PD-L2 Protein, Mouse (219a.a, HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Mouse	HEK293
	PD-L2 Protein plays a critical role in the T-cell costimulatory signal, fostering proliferation and IFNG production independently of PDCD1. While interacting with PDCD1 inhibits T-cell proliferation, PD-L2 itself intricately promotes immune responses. The dynamic interplay emphasizes PD-L2's dual role in either promoting or inhibiting T-cell activation within the immune signaling network, showcasing intricate regulatory mechanisms. PD-L2 Protein, Mouse (219a.a, HEK293, His) is the recombinant mouse-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Mouse (219a.a, HEK293, His) is 200 a.a., with molecular weight of 31-40 kDa.

HY-P72407

	PD-L2 Protein, Human (Biotinylated, HEK293, His-Avi) PD-1 Ligand 2; PDCD1 Ligand 2; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P72492

	PD-L2 Protein, Human (HEK293, His) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (HEK293, His) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72491

	PD-L2 Protein, Mouse (200a.a, HEK293, Fc) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Mouse	HEK293
	PD-L2 Protein plays a critical role in the T-cell costimulatory signal, fostering proliferation and IFNG production independently of PDCD1. While interacting with PDCD1 inhibits T-cell proliferation, PD-L2 itself intricately promotes immune responses. The dynamic interplay emphasizes PD-L2's dual role in either promoting or inhibiting T-cell activation within the immune signaling network, showcasing intricate regulatory mechanisms. PD-L2 Protein, Mouse (200a.a, HEK293, Fc) is the recombinant mouse-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L2 Protein, Mouse (200a.a, HEK293, Fc) is 200 a.a., with molecular weight of 70-80 kDa.

HY-P72493

	PD-L2 Protein, Rhesus macaque/Cynomolgus (HEK293, His) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Rhesus Macaque;Cynomolgus	HEK293
	PDCD1LG2 is an immune checkpoint receptor ligand that binds to PD-1 to activate pathways that inhibit TCR/ BCR-mediated immune cell activation. PDCD1LG2 can inhibit T-cell proliferation and inflammatory cytokine production. The expression of PDCD1LG2 on mouse tumor cells inhibits cytotoxic T-cell-mediated immune responses and can be used as a biomarker or prognostic indicator. PD-L2 Protein, Rhesus macaque/Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L2 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70734

	PD-L2 Protein, Human (HEK293, mFc) Programmed Cell Death 1 Ligand 2; PD-1 Ligand 2; PD-L2; PDCD1 Ligand 2; Programmed Death Ligand 2; Butyrophilin B7-DC; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-mFc labeled tag.

HY-P70964

	PD-L2 Protein, Rhesus macaque/Cynomolgus (HEK293, Fc) Programmed Cell Death 1 Ligand 2; PD-1 Ligand 2; PD-L2; PDCD1 Ligand 2; Programmed Death Ligand 2; Butyrophilin B7-DC; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Rhesus Macaque;Cynomolgus	HEK293
	PDCD1LG2 is an immune checkpoint receptor ligand that binds to PD-1 to activate pathways that inhibit TCR/ BCR-mediated immune cell activation. PDCD1LG2 can inhibit T-cell proliferation and inflammatory cytokine production. The expression of PDCD1LG2 on mouse tumor cells inhibits cytotoxic T-cell-mediated immune responses and can be used as a biomarker or prognostic indicator. PD-L2 Protein, Rhesus macaque/Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77879

	VISTA/B7-H5 Protein, Human (HEK293, Fc) B7H5; B7-H5; VISTA; VSIR ; PD1H; PD-1H; 4632428N05Rik; C10orf54; Dies1; Gi24; PP2135; SISP1	Human	HEK293
	VISTA/B7-H5 protein, an immunoregulatory receptor, inhibits T-cell response and may regulate embryonic stem cell differentiation by inhibiting BMP4 signaling. It also stimulates MMP14-mediated MMP2 activation, suggesting a role in matrix metalloproteinase processes. These roles highlight the significance of VISTA/B7-H5 in immune regulation, embryonic development, and extracellular matrix dynamics. VISTA/B7-H5 Protein, Human (HEK293, Fc) is the recombinant human-derived VISTA/B7-H5 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VISTA/B7-H5 Protein, Human (HEK293, Fc) is 162 a.a., with molecular weight of 70-80 kDa.

HY-P72428

	VISTA/B7-H5 Protein, Mouse (159a.a, HEK293, His) V-type immunoglobulin domain-containing suppressor of T-cell activation; Vsir; Dies1; PD-1H; VISTA	Mouse	HEK293
	VISTA/B7-H5 Protein is a type I transmembrane protein expressed primarily in white blood cells that inhibits T cell function. VISTA/B7-H5 Protein promotes embryonic stem cell differentiation by inhibiting BMP4 signaling and stimulates MMP14 mediated MMP2 activation. VISTA/B7-H5 Protein is highly expressed in tumors. VISTA/B7-H5 Protein, Mouse (159a.a, HEK293, His) is the recombinant mouse-derived VISTA/B7-H5 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VISTA/B7-H5 Protein, Mouse (159a.a, HEK293, His) is 159 a.a., with molecular weight of 30-40 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81839

	PD-L2 Antibody (YA1584) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	WB	Human, Rat
	PD L2 Antibody (YA1584) is a biotin-conjugated non-conjugated IgG antibody, targeting PD L2, with a predicted molecular weight of 31 kDa (observed band size: 31 kDa). PD L2 Antibody (YA1584) can be used for WB experiment in human, rat background.

HY-P81169A

	PD-1 Antibody(YA3401) Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.	WB, IHC-P, ICC/IF, FC	Human
	PD-1 Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-PD-1 monoclonal antibody. PD-1 Antibody can be used for: WB, IHC-P, Flow-Cyt, IF/ICC expriments in human background without labeling.

HY-P83254

	alpha/beta Synuclein Antibody (YA2999) alpha synuclein; beta synuclein; NACP; PD1; SNCA; SNCB	WB, ICC/IF, FC	Human, Mouse, Rat
	alpha/beta Synuclein Antibody (YA2999) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2999), targeting alpha/beta Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha/beta Synuclein Antibody (YA2999) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.

HY-P81603

	PD-L2 Antibody (YA1348) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	FC, ELISA	Human
	PDL2 Antibody (YA1348) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1348), targeting PDL2. PDL2 Antibody (YA1348) can be used for FC, ELISA experiment in human background.

HY-P81839A

	PD-L2 Antibody (YA3391) PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273; PD L2; PDL2	WB, ICC/IF, FC, ELISA	Human, Mouse, Rat